'Next-generation' sequencing becomes 'now-generation' by Neafsey, Daniel E & Haas, Brian J
In  the  last  Genome  Biology  report  on  this  annual 
conference, Manolis Kellis noted in 2004 that sequencing 
had reached a mature state, in which the research com­
munity ‘took for granted that we can sequence, assemble, 
and align complete genomes’ (Genome Biol 2004, 5:324). 
The  technological  innovations  of  the  next  few  years, 
which  shifted  sequencing  from  the  Sanger­style  long 
reads used to complete the first human genome to short 
‘next­generation’ reads, required a second wave of inno­
vation to prepare samples for sequencing and deal with 
the new format of the resulting data. Finally, as attendees 
of  the  Advances  in  Genome  Biology  &  Technology 
conference learned in February, the field can once again 
begin to take for granted our ability to effectively produce 
and process the copious sequencing data that contem­
porary sequencing technologies more affordably provide. 
The maturation of these technologies creates interesting 
new analytical applications for sequencing.
Upstream: innovation in sequencing sample 
preparation
Many  presenters  highlighted  innovative  approaches  to 
simplify sequencing library preparation, expand the range 
of samples eligible for sequencing, or limit sequencing to 
specific  genomic  regions.  In  describing  the  Wellcome 
Trust  Sanger  Centre’s  sequencing  pipeline,  Harold 
Swerdlow  (Sanger  Centre,  Hinxton,  UK)  detailed  the 
degree  to  which  amplification­free  Illumina  library 
construc  tion  reduces  the  effect  of  GC  composition  on 
sequen  cing  coverage.  Andi  Gnirke  (Broad  Institute, 
Cambridge, USA) described approaches by which base 
composition coverage bias can be minimized during the 
amplification phase of Illumina library construction, for 
instances  where  circumstances  do  not  permit  ampli­
fication­free libraries.
Hybrid selection has become a widely adopted means 
by which to selectively sequence just the exonic portion 
of  the  human  genome,  or  other  specific  regions  of 
interest. By designing oligonucleotides complementary to 
targeted regions and then hybridizing those oligonucleo­
tides with genomic DNA on a chip or in solution, signifi­
cant enrichment in sequencing coverage of the resulting 
captured DNA may be achieved. Many talks reported use 
of  this  technology,  such  as  those  from  Obi  Griffith 
(Lawrence Berkeley National Laboratory, Berkeley, USA) 
on breast cancer pharmacogenomics and Donna Muzny 
(Baylor College of Medicine, Houston, USA) on the use 
of  exon  or  regional  capture  at  Baylor  to  characterize 
mutations associated with tumors, autism, and the 1000 
Genomes Project, using Illumina or SOLiD sequencing. 
Hybrid  selection  is  also  beginning  to  be  used  for 
sequencing disease genomes from clinical samples ­ for 
example, hepatitis C virus (Reinhold Pollner, Gen­Probe, 
San Diego, USA). Despite the falling cost of sequencing, 
selective sequencing of genomic regions of interest will 
probably remain a key application into the future.
Downstream: innovation in data handling and 
analysis
The  utility  of  cheap,  abundant  sequencing  data  is 
amplified by the research community’s growing ability to 
effectively use and analyze the data. The short read nature 
of  current  generation  sequencing  necessitates  signifi­
cantly  higher  sequencing  coverage  than  long  reads  for 
most applications, and so analysis algorithms and hard­
ware  must  be  capable  of  dealing  not  only  with  the 
shortness of the reads, but also their extreme abundance. 
Just  as  early  adopters  of  the  Pacific  Biosciences  RS 
sequencer have begun to report increasingly long reads 
from  that  new  sequencing  platform,  the  community 
seems to have become adept at dealing with the chal­
lenges  of  short  reads.  Steven  Salzberg  (University  of 
Maryland, College Park, USA) described a collection of 
software  tools  for  short­read  alignment  and  analysis 
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© 2011 BioMed Central Ltd(Bowtie, TopHat, and Cufflinks). Bowtie belongs to a new 
breed of alignment tools that use the Burrows­Wheeler 
transform, which can compact a human reference genome 
assembly into as little as 1.1 GB of memory such that it 
allows ultra­fast mapping of short reads to the reference.
Although  mapping  of  short  reads  can  benefit  from 
reduced hardware requirements, the hardware needs for 
short read assembly continue to grow, especially as short 
read assembly algorithms begin to tackle larger genomes. 
David  Jaffe  (Broad  Institute)  described  the  algorithmic 
and computational challenges of generating ‘good cheap 
genome  assemblies’  as  implemented  in  the  new 
ALLPATHS­LG assembly software. Through a combina­
tion  of  this  new  assembly  software,  a  large  memory 
server (512 GB RAM), and a specialized laboratory recipe 
for  genome  sequencing  involving  Illumina  paired  frag­
ments,  Jaffe  reported  on  being  able  to  generate  draft 
assemblies for 15 vertebrate genomes with quality approach­
ing that derived from capillary­based sequencing.
Not  having  access  to  high  performance  computing 
resources can be a serious impediment to working with 
next­generation  sequencing  data,  and  for  many,  cloud 
computing  is  becoming  an  attractive  solution.  Toby 
Bloom  (Broad  Institute)  described  her  experiences  in 
migrating the Broad Institute’s next­generation sequence 
analysis  pipeline  to  the  Amazon  cloud.  Cloud­based 
analysis  presented  certain  difficulties,  most  notably  a 
need to keep moving data around within the cloud to 
match disk storage and performance with targeted com­
pu  ting resources, but as cloud computing services con­
tinue to evolve and improve it will become a viable and 
effective analysis solution for small sequencing centers.
Whether one computes locally or uses the cloud, data 
processing  and  analysis  workflows  can  be  complex  to 
navigate and maintain. James Taylor (Emory University, 
Atlanta,  USA)  described  how  the  Galaxy  workflow 
system  can  help.  The  new  development  of  the  Galaxy 
Tool Shed, akin to an app store for Galaxy, is destined to 
further  popularize  the  system  among  the  growing 
community of users.
New sequencing-based discoveries and 
applications
Now that genome sequencing data are not only inexpen­
sive  but  intelligible,  the  question  many  seemed  to  be 
wrestling with at this conference was how to make the 
data  useful  outside  a  research  context.  Sequencing 
instru  ment manufacturers are doing their part to expand 
the territory of their technology to outside of the research 
laboratory. The Ion Torrent Personal Genome Machine 
from Life Technologies, which debuted at last year’s con­
ference, has now been deployed at a number of sites and 
boasts  an  extremely  short  run  time  (only  2  hours)  for 
rapid  data  generation.  Illumina  debuted  their  MiSeq 
machine, which costs significantly less than their other 
sequencing instruments and is also capable of producing 
sequencing data in hours rather than days.
Several cancer­themed talks discussed the potential for 
sequencing to have an impact on disease treatment and 
prognosis. David Craig (TGEN, Phoenix, USA) discussed 
data from a clinical trial designed to discover clinically 
actionable  features  of  breast  cancer  patients  using 
sequen  cing, but noted that sequencing and analysis of a 
patient’s  genome  and  transcriptome  data  required 
6  weeks  of  time.  Richard  Weinshilboum  (Mayo  Clinic, 
Rochester,  USA)  described  functional  validation  of 
genome­wide association study (GWAS) signals, in this 
case for breast cancer. He highlighted the utility of such 
studies for identifying markers associated with treatment 
response or tumor sensitivity to drugs such as aromatase 
inhibitors  and  selective  estrogen­receptor  modulators, 
but noted that the research investment to discover such 
markers  can  be  massive  (30,000  subjects  studied  over 
many  years)  and  might  not  be  broadly  replicable  for 
diverse diseases and drugs. Eric Boerwinkle (University 
of  Texas  School  of  Public  Health,  Houston,  USA)  also 
described  the  challenges  imposed  by  follow­up 
investigations  of  GWAS  hits.  Boerwinkle  and 
collaborators investigated a single nucleotide variant that 
conferred  a  relative  risk  of  1.3  for  atherosclerosis. 
Although small, this relative risk would boost the 10­year 
risk  of  coronary  heart  disease  from  15%  to  21%  in  a 
typical patient, and could lead to a different treatment 
regimen  for  approximately  10%  of  athero  sclerosis 
patients if physicians were to commonly have access to 
genotype data for this locus. Carlos Bustamante (Stanford 
University,  Stanford,  USA)  pointed  out  that  current 
GWASs are biased towards European populations, and 
the ancestry of a candidate disease­correlated marker in 
the genome must be taken into consideration before the 
data can be considered clinically relevant.
Several  talks  addressed  the  potential  benefits  and 
pitfalls  of  personalized  genome  data.  James  Lupski 
(Baylor College of Medicine) described his efforts to use 
whole genome sequencing to successfully hunt down the 
genetic variants responsible for a rare neuropathy that 
has  afflicted  him  and  his  family,  and  points  out  that 
genomic  data  from  one’s  relatives  can  be  much  more 
useful in such applications than data from the population 
at  large.  Joe  Beery  (Life  Technologies,  Carlsbad,  USA) 
described a frustrating 14­year journey of working with 
medical professionals to diagnose and treat a mysterious 
illness in his twin children. Whole­genome sequencing of 
his twins using SOLiD technology identified mutations 
responsible  for  dopa­responsive  dystonia,  a  pharma  co­
logically treatable disease.
Though these examples plainly illustrate the potential 
value of personalized genome sequencing, clear policies 
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and clinicians is essential. Ellen Wright Clayton (Vander­
bilt University, Nashville, USA) advanced the notion that 
it is imperative to develop a policy framework and decide 
when genetic data are ready for prime­time in medicine. 
As sequencing data become increasingly cheaper, ubiqui­
tous, and informative, clinicians and the public will need 
to  be  made  aware  that,  in  addition  to  the  genome,  a 
multi  tude of other factors, such as the physical environ­
ment, the microbiome, epigenome, and pleiotropy, can 
have complex roles in sculpting phenotype.
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